However, acute myelogenous leukemia stem cells exhibit reduced expression of this marker [25], thus clouding interpretation of the association of CD90 expression with a stem-like phenotype and drug resistance across diverse cancer types. Here, THY1 is linked to acute myeloid leukemia.